Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease
Cannabinoids: Novel medicines for the treatment of Huntington’s disease
Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB(1) and CB(2) receptors
Controlled clinical trial of cannabidiol in Huntington’s disease
Prospects for cannabinoid therapies in basal ganglia disorders
Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice
